. 2025 Mar 31;10(1):Doc009. doi: 10.34865/mb9997e10_1or

Tab.5. Carcinogenicity study with N,N-dimethyl-p-toluidine in mice.

Author:	NTP 2012
Substance:	N,N-dimethyl-p-toluidine (purity: > 99%)
Species:	mouse, B6C3F1, groups of 50 ♂, 50 ♀
Administration route:	oral, gavage
Dose:	0, 6, 20, 60 mg/kg body weight and day
Duration:	2 years, 5 days/week
Toxicity:	6 mg/kg body weight and day and above: liver: hypertrophy, necrosis, nose: ♀: hyperplasia, metaplasia; 20 mg/kg body weight and day and above: lungs: ♀: alveolar epithelium hyperplasia, forestomach: ♀: hyperplasia (Section 5.2.2)
		Dose [mg/kg body weight]
		0	6	20	60
surviving animals	♂	34/50 (68%)	36/50 (72%)	31/50 (62%)	36/50 (72%)
surviving animals	♀	43/50 (86%)	40/50 (80%)	39/50 (78%)	32/50 (64%)
tumours and pre-neoplastic lesions
liver:
hepatocellular adenomas, multiple	♂	17/50 (34%)	19/50 (38%)	27/50 (54%)^*	26/50 (52%)^*
hepatocellular adenomas, multiple	♀	2/50 (4%)	6/50 (12%)	29/50 (58%)^**	35/50 (70%)^**
hepatocellular adenomas	♂	29/50 (58%)	34/50 (68%)	37/50 (74%)	36/50 (72%)
hepatocellular adenomas	♀	17/50 (34%)	19/50 (38%)	37/50 (74%)^**	44/50 (88%)^**
hepatocellular carcinomas	♂	22/50 (44%)	25/50 (50%)	30/50 (60%)	36/50 (72%)^*
hepatocellular carcinomas	♀	6/50 (12%)	13/50 (26%)^*	18/50 (36%)^**	31/50 (62%)^**
hepatoblastomas	♂	1/50 (2%)	5/50 (10%)	10/50 (20%)^*	8/50 (16%)^*
hepatoblastomas	♀	0/50	1/50 (2%)	0/50	4/50 (8%)^*
lungs:
bronchiolar-alveolar adenomas	♀	2/50 (4%)	4/50 (8%)	8/50 (16%)^*	12/50 (24%)^*
bronchiolar-alveolar adenomas and carcinomas	♀	2/50 (4%)	5/50 (10%)	9/50 (18%)^*	13/50 (26%)^*
forestomach:
squamous cell papillomas	♂	1/50 (2%)	1/50 (2%)	0/50	3/50 (6%)
squamous cell papillomas	♀	1/50 (2%)	5/50 (10%)	6/50 (12%)^*	7/50 (14%)^*
squamous cell papillomas or carcinomas	♀	1/50 (2%)	6/50 (12%)	6/50 (12%)^*	7/50 (14%)^*

p ≤ 0.05

^**

p ≤ 0.01